What Is a Skin Bank and How Does It Work?

A skin bank is a facility that collects, processes, preserves, and distributes donated human skin for transplantation, functioning much like a blood bank but for tissue. Most of the skin it stores comes from deceased donors and is used primarily as a temporary biological dressing for severe burn patients, though its applications have expanded well beyond burns. The concept dates back decades, with one of the earliest national-scale operations established in the Netherlands in 1976, and the field has since developed sophisticated preservation techniques that allow donated skin to be stored for months or even years before use.

Where the Skin Comes From

The vast majority of skin stored in a skin bank comes from cadaveric donors, meaning people who have died and whose families have consented to tissue donation. In some cases, living first-degree relatives donate skin directly for a specific patient, but this is far less common and typically limited to acute situations where a banked supply is unavailable. Cadaveric skin can be recovered within hours of death, usually from the back, thighs, and legs, where large, relatively uniform sheets can be harvested without affecting the appearance of the body for funeral arrangements.

Not every potential donor qualifies. Skin banks screen donors using the same rigorous serological and molecular testing applied to organ donors, checking for HIV, hepatitis B and C, syphilis, and other transmissible infections. A study of one regional skin bank in Italy found that about 16% of cadaveric donors were ruled ineligible after screening, highlighting how substantial the attrition rate can be even before any skin is processed.¹ Medical history, cause of death, and the condition of the skin itself are also evaluated. Donors with certain cancers, autoimmune diseases, or signs of skin infection are excluded.

Harvesting and Initial Processing

Once a donor is cleared, trained retrieval teams harvest the skin using a device called a dermatome, which shaves off thin, controlled layers of skin at a precise thickness. These are split-thickness grafts, meaning they include the outer layer of skin (the epidermis) and a portion of the underlying dermis, but not the full depth. The dermatome can be adjusted to cut grafts of varying widths and thicknesses depending on clinical need.² The harvested sheets are placed in a transport medium, often a chilled solution like Ringer’s Lactate, and moved quickly to the processing lab.

At the lab, the skin undergoes decontamination. This typically involves soaking the tissue in antibiotic and antifungal solutions to kill bacteria and reduce the risk of transmitting infection to the eventual recipient. A systematic review of disinfection methods found that the most effective approaches used either peracetic acid at low concentrations or gamma irradiation at lower temperatures, both of which achieved the greatest reductions in contamination.³ Many banks use multi-step antibiotic cocktails, sometimes applied both immediately after retrieval and again after further processing. Research at one Italian tissue bank compared two different antibiotic cocktails and found that a combination of gentamicin, meropenem, and vancomycin outperformed an older cocktail in killing bacteria across multiple tissue types.⁴

How Skin Is Preserved

Preservation is the core technical challenge of skin banking. Fresh skin deteriorates rapidly, so extending its shelf life without destroying its biological usefulness requires careful methods. Two main approaches dominate the field: cryopreservation and glycerolization. Each has distinct trade-offs, and the choice between them shapes how a skin bank operates and what kind of clinical results it can offer.

Cryopreservation

Cryopreservation freezes skin at extremely low temperatures, usually in the vapor phase of liquid nitrogen, after treating it with a cryoprotectant to minimize ice-crystal damage to cells. The two most common cryoprotectants are glycerol and dimethyl sulfoxide (DMSO). One study found that skin cryopreserved with DMSO retained higher cell viability than skin preserved with glycerol.⁵ However, another investigation comparing the two cryoprotectants found them to be roughly equivalent, with differences depending partly on how the skin was transported before freezing.⁶ The key advantage of cryopreservation is that it keeps a meaningful fraction of skin cells alive, which means the graft can actively participate in wound healing when applied to a patient.

Glycerolization

Glycerolization takes a fundamentally different approach. The skin is soaked in a high concentration of glycerol, typically around 85%, and then stored at refrigerator temperature rather than frozen. This method was pioneered by the Euro Skin Bank in 1984 and has become widely adopted, especially in resource-limited settings.⁷ The trade-off is significant: glycerolization destroys the living cells in the skin, rendering the graft non-viable. What remains is the structural framework, the collagen and proteins that give skin its physical properties. Despite being “dead” tissue, glycerol-preserved skin still functions well as a temporary wound covering. The glycerol itself has antibacterial and antiviral properties and also reduces the graft’s immunogenicity, meaning the recipient’s immune system is less likely to mount a fierce rejection response.

The practical appeal of glycerolization is its simplicity. It does not require liquid nitrogen storage, specialized freezers, or the careful thawing protocols that cryopreserved skin demands. One analysis estimated that running an in-house glycerol-preservation skin bank cut costs by roughly 90% compared to purchasing grafts from a large external supplier like the Euro Skin Bank.⁸ For hospitals in low- and middle-income countries treating large numbers of burn patients, that difference can determine whether allograft skin is available at all.

How the Two Methods Compare Clinically

A porcine wound model study compared glycerol-preserved and cryopreserved allografts side by side. Cell viability was substantially lower in glycerol-preserved skin (about 9%) compared to cryopreserved skin (about 21%), and both lagged far behind fresh skin (about 59%). Yet the initial take rate on the wound was actually higher for glycerol-preserved grafts in the first two days, and by one week the take rates were nearly equal. The study concluded that the preservation method was not the deciding factor in wound healing outcomes.⁹ A separate clinical comparison confirmed that cryopreservation yields a more viable product, but both methods maintain the structural integrity of the tissue well enough for clinical use.¹⁰

What Happens When Allograft Skin Is Applied to a Patient

Skin allografts are not permanent replacements. They serve as biological dressings that protect the wound, reduce fluid loss, limit bacterial invasion, and create conditions for the patient’s own skin to eventually take over. In burn care, this is critical. A patient with burns covering a large percentage of their body may not have enough healthy skin left to provide autografts (transplants of their own skin) for every wound at once. Allograft skin buys time by covering the exposed areas while the patient’s donor sites heal enough to be re-harvested.¹¹

Clinically, allograft skin has been shown to outperform topical antimicrobial dressings in partial-thickness burns, reducing complications and shortening hospital stays.¹² Fresh allograft from living relatives, when available, offers the highest viability and can improve wound-bed vascularization and decrease microbial contamination, helping prepare the wound for a later definitive autograft.¹³

Why the Body Eventually Rejects Allograft Skin

Because allograft skin comes from another person, the recipient’s immune system treats it as foreign tissue. Immune cells recognize proteins on the surface of donor cells that differ from the recipient’s own, and this triggers an inflammatory response aimed at destroying the graft. The process involves multiple arms of the immune system: T cells that attack donor cells directly, antibodies that target foreign tissue, and natural killer cells that respond to the absence of familiar surface markers on the graft.¹⁴ This rejection typically begins within one to three weeks, depending on the patient’s immune status and the type of graft used.

This is why allografts in burn care are understood to be temporary from the start. Glycerol-preserved grafts, because their cells are already dead, provoke a weaker immune reaction and tend to stay in place somewhat longer before needing removal. The goal is never for the allograft to become a permanent part of the patient’s body. It is a bridge, holding the wound together until the patient’s own skin can be grafted over it.

Decellularized Skin as a Step Further

Some skin banks now process donated skin into decellularized dermal matrices, which takes the idea behind glycerolization a step further. Instead of merely killing the cells, the processing removes all cellular material entirely, leaving behind only the structural scaffold of the dermis: the collagen fibers, basement membrane, and extracellular matrix proteins. One protocol using purely chemical agents (no enzymes) demonstrated that key structural proteins like collagen types I, III, and IV and laminin were preserved after decellularization, while residual genetic content was reduced to negligible levels.¹⁵¹⁶

Because there are no donor cells left to trigger rejection, decellularized matrices can remain in the body permanently. The patient’s own cells gradually migrate into the scaffold and repopulate it, effectively using the donated tissue as a template to rebuild their own dermis. These products are used in reconstructive surgery, hernia repair, and complex wound management, not just burns.

Uses Beyond Burns

While severe burns remain the primary reason skin banks exist, their products are increasingly used for chronic wounds that resist conventional treatment. Skin bank bioproducts are currently used for conditions including venous and arterial leg ulcers, pressure ulcers, diabetic foot ulcers, post-traumatic lesions, and wounds from Mohs surgery for skin cancer.¹⁷

Diabetic foot ulcers are a particularly active area of research. A randomized trial of 100 patients with non-healing diabetic foot ulcers compared a cryopreserved bioactive split-thickness skin allograft to standard wound care. At 12 weeks, 76% of the allograft group had healed compared to 36% in the standard-care group.¹⁸ A systematic review of multiple randomized trials confirmed that various skin allograft products achieved statistically significant improvements in 12-week wound closure for chronic lower-extremity wounds, though results varied by product.¹⁹

Emergency Preparedness and the Supply Problem

Skin banks face a persistent supply challenge: demand for allograft skin consistently exceeds what is available. This gap becomes especially dangerous during mass-casualty events like building collapses, industrial explosions, or large-scale fires. In the United States, the skin banking landscape has consolidated over the years into a small number of nationally focused suppliers. These organizations are essentially competitors under normal circumstances, but they coordinate during crises to distribute lifesaving tissue where it is needed most.²⁰

Planning for these scenarios has become a formal part of skin bank operations. A study modeling mass-disaster preparedness in Poland estimated that a minimum strategic reserve of 600,000 square centimeters of allograft skin would be needed to handle a large-scale emergency, and concluded that the existing donation system was inadequate to maintain such a reserve. The researchers proposed organizational and legal changes, including expanded roles for non-physician team members in tissue retrieval and public awareness campaigns to increase donation rates.²¹ Similar supply pressures have driven the development of national skin bank networks in countries from India to Australia, where regional banks have had to develop creative strategies to stretch limited supply across large geographic areas.²²

Quality Control and Regulation

Skin banks operate under strict regulatory frameworks that vary by country but share common principles. In the United States, the Food and Drug Administration classifies human skin allografts as human cells, tissues, and cellular and tissue-based products (HCT/Ps) and regulates their recovery, processing, storage, and distribution. The American Association of Tissue Banks (AATB) provides additional voluntary accreditation standards that most reputable banks follow. In Europe, the European Union Tissue and Cells Directives set minimum quality and safety requirements across member states.

At the operational level, quality assurance involves documentation at every step: donor screening records, processing logs, environmental monitoring of storage facilities, and traceability systems that can link any piece of distributed skin back to its donor and every step of its handling. The Israel National Skin Bank, for instance, developed its protocol by combining international skin banking guidelines with its own research to create a comprehensive framework covering procurement, processing, preservation, storage, and evaluation of graft performance.²³ Microbiological cultures are taken at multiple points during processing, and any batch that tests positive for contamination after final processing is discarded.

Consent, Ethics, and the Perception Gap

One of the less visible challenges facing skin banks is public perception. While organ donation has gained broad acceptance in many countries, tissue donation, and skin donation in particular, can provoke more complicated emotional responses from families. A study exploring the perspectives of family members who were asked to consent to skin donation found that even among those who agreed, the decision carried both positive and negative psychological weight. Among those who refused, the researchers identified a previously undocumented concern they described as the “animalization of the donor,” a fear that harvesting skin would somehow dehumanize their loved one’s body.²⁴

This perception gap contributes directly to the supply shortage. Unlike kidneys or hearts, skin donation does not save a life in the dramatic, single-recipient way that makes organ donation emotionally compelling for families. The benefit is distributed across many patients, often strangers, and the concept of donating skin can feel more viscerally uncomfortable than donating internal organs that are hidden from view. Addressing these attitudes is increasingly recognized as essential to improving donation rates, and several national programs have begun integrating skin donation awareness into their broader organ and tissue donation campaigns.

Alternatives to Human Allograft Skin

The persistent shortage of human donor skin has pushed researchers to explore biological alternatives. Xenografts, skin from other species, have been used for decades. Porcine skin is the most established xenograft in clinical practice, with properties that overlap meaningfully with human skin. More recently, Nile tilapia fish skin has attracted attention as a wound dressing for burns. The fish skin contains collagen and has a physical structure that resembles human skin more closely than you might expect. Clinical studies have shown that patients with superficial partial-thickness burns treated with tilapia skin experienced less pain, needed fewer dressing changes, and used fewer painkillers compared to conventional management.²⁵ This approach has gained particular traction in Brazil, where tilapia are abundant and the cost of imported human allograft is prohibitive for many hospitals.

On the more experimental end, 3D bioprinting aims to fabricate skin constructs from living cells deposited in precise layers. Laser-assisted bioprinting has been used to create dermal substitutes by placing fibroblasts onto a stabilizing matrix, then grafting the construct onto full-thickness wounds in animal models. After 11 days, the printed grafts adhered well, blood vessels began growing into the construct from the wound bed and edges, and the resulting dermal structure mimicked the normal density pattern of human skin, with a dense upper layer and a sparser lower layer.²⁶ These technologies remain years from routine clinical use, but they represent a potential future where the supply of wound-covering materials is no longer limited by the number of willing donors.

How Skin Banks Have Spread Globally

The geographic expansion of skin banking reflects both the growing recognition of its clinical importance and the challenge of adapting sophisticated tissue-processing systems to different healthcare environments. The Euro Skin Bank, established in the Netherlands in 1976, was a pioneer in developing preservation technologies and demonstrated the immunological benefits of glycerolization by 1983.²⁷ Its model and technical expertise were later exported to developing countries, including India, where the National Burns Centre in Mumbai collaborated with the Euro Skin Bank and Rotary International to establish an effective cadaveric skin banking system in 2009. That model has since been replicated in other Indian states to serve the country’s large burn population.²⁸

The pattern is similar across much of Africa, Southeast Asia, and Latin America: burn injuries are common, specialized burn centers are few, and allograft skin has historically been either unavailable or too expensive to import. Glycerol-preserved skin banking, with its lower infrastructure requirements, has become the preferred entry point for countries building their first tissue-banking capabilities. What began as a niche service supporting a single hospital has become a global network of facilities, each adapting its protocols to local regulations, donor demographics, and clinical needs.